Macrophage Activation Syndrome Market in the 6MM to Witness Upsurge in Growth at a CAGR of 24.7% During the Forecast Period (2025-2034) | DelveInsight
The macrophage activation syndrome market is experiencing steady growth, driven by broadened treatment options, improved survival outcomes, and the launch of emerging therapies such as targeting SIRP-α/β1/γ (ELA026), targeting Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) (Plonmarlimab), IL-18 inhibitor (Tadekinig alfa), dual IL-1β and IL-18 inhibitor (MAS825), and others.
LAS VEGAS, Jan. 13, 2026 /PRNewswire/ -- DelveInsight's Macrophage Activation Syndrome Market Insights report includes a comprehensive understanding of current treatment practices, macrophage activation syndrome emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Macrophage Activation Syndrome Market Summary
Discover the new macrophage activation syndrome treatment @ Macrophage Activation Syndrome Treatment Market
Key Factors Driving the Growth of the Macrophage Activation Syndrome Market
Macrophage Activation Syndrome Market Analysis
Macrophage Activation Syndrome Competitive Landscape
The MAS drugs in clinical trials include ELA026 (Electra Therapeutics), Plonmarlimab (TJ Biopharma), Tadekinig alfa (AB2 Bio), MAS825 (Novartis), and others.
Electra Therapeutics' ELA026 is a first-in-class monoclonal antibody designed to target Signal Regulatory Proteins (SIRPs) expressed on the surface of myeloid cells and T lymphocytes, enabling the selective elimination of disease-driving immune cells. This innovative mechanism offers potential therapeutic value across a broad range of conditions.
AB2 Bio's Tadekinig alfa is a novel recombinant form of human interleukin-18 binding protein (IL-18BP) that neutralizes IL-18, a key pro-inflammatory cytokine. In healthy individuals, excess endogenous IL-18BP maintains systemic free IL-18 at undetectable levels. Tadekinig alfa is currently being evaluated in a Phase III clinical trial.
In January 2025, AB2 Bio announced an option and licensing agreement with Nippon Shinyaku covering the United States. Under this agreement, Nippon Shinyaku holds exclusive commercialization rights for Tadekinig alfa in its lead indication, primary monogenic IL-18–driven hyperinflammatory syndrome associated with NLRC4 mutations and XIAP deficiency, across the US, including Guam, Puerto Rico, and the US Virgin Islands. AB2 Bio retains rights for all other indications within these territories, as well as for all indications outside the US. AB2 Bio continues to advance preparations for submission of a US Biologics License Application (BLA) for Tadekinig alfa in this indication.
The anticipated launch of these emerging therapies are poised to transform the macrophage activation syndrome market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the macrophage activation syndrome market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
Discover more about the macrophage activation syndrome drugs @ Macrophage Activation Syndrome Drugs Market
Recent Developments in the Macrophage Activation Syndrome Market
What is Macrophage Activation Syndrome?
Macrophage activation syndrome (MAS) is a rare, severe, and potentially life-threatening hyperinflammatory condition characterized by uncontrolled activation and proliferation of macrophages and T lymphocytes, leading to a cytokine storm. It is most commonly associated with systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still's disease. Still, it can also occur in the context of infections, malignancies, or other autoimmune and autoinflammatory disorders. MAS results in excessive immune-mediated tissue damage and is marked by clinical features such as persistent high fever, hepatosplenomegaly, cytopenias, liver dysfunction, coagulopathy, and markedly elevated inflammatory markers, particularly ferritin. Prompt recognition and aggressive immunosuppressive treatment are critical, as MAS can rapidly progress to multi-organ failure if left untreated.
Macrophage Activation Syndrome Epidemiology Segmentation
The macrophage activation syndrome epidemiology section provides insights into the historical and current macrophage activation syndrome patient pool and forecasted trends for the leading markets. MAS spans both pediatric and adult populations, occurring most frequently in children with sJIA and KD. In contrast, adult cases are more common in AOSD, SLE, and secondary triggers such as infections or malignancies.
The macrophage activation syndrome treatment market report proffers epidemiological analysis for the study period 2020–2034 in the leading markets, segmented into:
Macrophage Activation Syndrome Market Report Metrics
Details
Study Period
2020–2034
Coverage
7MM [The United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Macrophage Activation Syndrome Market CAGR (6MM)
24.7 %
Macrophage Activation Syndrome Market Size in 2024 in 6MM
USD 110 Million
Key Macrophage Activation Syndrome Companies
Electra Therapeutics, TJ Biopharma, AB2 Bio, Novartis, Deepcure, Sobi, and others
Key Macrophage Activation Syndrome Therapies
ELA026, Plonmarlimab (TJM2/TJ003234), Tadekinig alfa (r-hIL-18BP), MAS825, GAMIFANT, and others
Scope of the Macrophage Activation Syndrome Market Report
Download the report to understand what is the latest research on macrophage activation syndrome @ New Macrophage Activation Syndrome Medication
Table of Contents
1
Macrophage Activation Syndrome Market Key Insights
2
Macrophage Activation Syndrome Market Report Introduction
3
Executive Summary of Macrophage Activation Syndrome (MAS)
4
Key Events
5
Epidemiology and Market Forecast Methodology
6
MAS Market Overview at a Glance
6.1
Clinical Landscape (Analysis by Molecule Type, Phase, and Route of Administration [RoA])
6.2
Market Share of MAS by Therapies (%) in the 6MM in 2024
6.3
Market Share of MAS by Therapies (%) in the 6MM in 2034
7
Disease Background and Overview
7.1
Introduction
7.2
MAS Diseases
7.2.1
AOSD
7.2.2
sJIA
7.2.3
SLE
7.2.4
Kawasaki Disease
7.3
Symptoms
7.4
Major Triggers of sHLH
7.5
Pathogenesis
7.6
Diagnosis
7.7
Diagnostic Guidelines
8
Macrophage Activation Syndrome Treatment
9
Epidemiology and Patient Population
9.1
Key Findings
9.2
Assumptions and Rationale
9.3
Total Diagnosed Prevalent Population of SLE in the 7MM
9.4
Total Diagnosed Prevalent Population of AOSD in the 7MM
9.5
Total Diagnosed Prevalent Population of sJIA in the 7MM
9.6
Total Incident Population of Kawasaki Disease in the 7MM
9.7
Total Diagnosed Prevalent Population of MAS in the 7MM
9.8
The United States
9.8.1
Total Diagnosed Prevalent Population of MAS in the United States
9.8.2
Gender-specific Diagnosed Prevalent Population of MAS in the United States
9.8.3
Total Treated Cases of MAS in the United States
9.9
EU4 and the UK
9.10
Japan
10
Macrophage Activation Syndrome Patient Journey
11
Marketed Macrophage Activation Syndrome Therapies
11.1
Details of Marketed Therapy
11.2
Emapalumab-lzsg (GAMIFANT): Sobi
11.2.1
Product Description
11.2.2
Regulatory Milestones
11.2.3
Other Developmental Activities
11.2.4
Summary of Pivotal Trials
11.2.5
Analyst Views
12
Emerging Macrophage Activation Syndrome Drugs
12.1
Key Cross Competition
12.2
ELA026: Electra Therapeutics
12.2.1
Product Description
12.2.2
Other Developmental Activities
12.2.3
Clinical Development
12.2.3.1
Clinical Trial Information
12.2.4
Safety and Efficacy
12.2.5
Analyst Views
12.2.6
ELA026-specific response
12.3
Plonmarlimab (TJM2/TJ003234): TJ Biopharma/I-Mab Biopharma (NovaBridge Biosciences)
12.4
Tadekinig Alfa (r-hIL-18BP): AB2 Bio
12.4.6
Tadekinig alfa-Specific response
12.5
MAS825: Novartis
13
MAS Market: 7MM Analysis
13.1
Key Findings
13.2
Macrophage Activation Syndrome Market Outlook
13.3
Conjoint Analysis
13.4
Key Macrophage Activation Syndrome Market Forecast Assumptions
13.5
Total Market Size of MAS in the 7MM
13.6
The United States Macrophage Activation Syndrome Market
13.6.1
Total Market Size of MAS in the United States
13.6.2
Total Market Size of MAS by Therapies in the United States
13.7
EU4 and the UK Macrophage Activation Syndrome Market Size
13.7
Japan Macrophage Activation Syndrome Market Size
14
Macrophage Activation Syndrome Market Unmet Needs
15
Macrophage Activation Syndrome Market SWOT Analysis
16
KOL Views on Macrophage Activation Syndrome
17
Macrophage Activation Syndrome Market Access and Reimbursement
17.1
The United States
17.2
In EU4 and the UK
17.2.6
Japan
17.3
Summary and Comparison of Market Access and Pricing Policy Developments in 2025
17.4
Market Access and Reimbursement of MAS Therapy
18
Bibliography
19
Macrophage Activation Syndrome Market Report Methodology
Related Reports
Systemic Lupus Erythematosus Market
Systemic Lupus Erythematosus Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key SLE companies including Biogen, Novartis, MorphoSys, Idorsia Pharmaceuticals, Viatris, RemeGen, UCB Pharma, Genentech, Bristol Myers Squibb, AbbVie, among others.
Adult-Onset Still's Disease Market
Adult-Onset Still's Disease Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key AOSD companies including Novartis, Swedish Orphan Biovitrum, Roche, Cerecor, AB2 Bio Ltd, among others.
Juvenile Idiopathic Arthritis Market
Juvenile Idiopathic Arthritis Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key JIA companies including Regeneron, Sanofi, AbbVie, Eli Lilly and Company, Incyte Corporation, Johnson & Johnson, Hope Biosciences, Bristol-Myers Squibb, UCB Biopharma, Novartis, among others.
Kawasaki Disease Market
Kawasaki Disease Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key Kawasaki disease companies including Green Cross Corporation, GC Biopharma Corp, Mitsubishi Tanabe Pharma Corporation, Centocor Inc., Amgen, Takeda, The Emmes Company LLC, among others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Shruti Thakur
[email protected]
+14699457679
www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
SOURCE DelveInsight Business Research, LLP